特集 : 国別レポートが13,000件から検索可能になりました!

特集 : 海外市場の委託調査がセミカスタムベースでお手軽にできます

株式会社グローバルインフォメーション
TEL: 044-952-0102
表紙
市場調査レポート

クローン病 - パイプライン製品の分析

Crohn's Disease (Regional Enteritis) - Pipeline Review, H1 2020

発行 Global Markets Direct 商品コード 232862
出版日 ページ情報 英文 623 Pages
即納可能
価格
本日の銀行送金レート: 1USD=107.13円で換算しております。
クローン病 - パイプライン製品の分析 Crohn's Disease (Regional Enteritis) - Pipeline Review, H1 2020
出版日: 2020年02月28日 ページ情報: 英文 623 Pages
担当者のコメント
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
概要

クローン病は、消化管内壁の炎症であり、人によって病変部位が異なります。主な症状は腹痛、激しい下痢、血便、潰瘍、食欲不振、体重減少などです。

当レポートでは、クローン病に対する治療薬の開発状況について調査分析し、パイプライン製品の概要、治験の段階別の製品の概要、主要企業プロファイル、薬剤のプロファイル、パイプライン製品の最新動向、最新ニュースとプレスリリースなどについて、体系的な情報を提供しています。

イントロダクション

クローン病の概要

治療薬の開発

クローン病:企業で開発中の治療薬

クローン病:大学/機関で研究中の治療薬

クローン病:パイプライン製品の概況

クローン病:企業で開発中の製品

クローン病:大学/機関で研究中の製品

クローン病の治療薬開発に従事している企業

クローン病:治療薬の評価

薬剤プロファイル

クローン病:最近のパイプライン動向

クローン病:休止中のプロジェクト

クローン病:開発が中止された製品

クローン病:製品開発のマイルストーン

付録

図表

List of Tables

  • Number of Products under Development for Crohn's Disease (Regional Enteritis), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..3), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..4), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..5), H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..6), H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..2), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..3), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..4), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..5), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..6), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..7), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..8), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..9), H1 2020
  • Products under Development by Companies, H1 2020 (Contd..10), H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..2), H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..3), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..2), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..3), H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Crohn's Disease (Regional Enteritis) - Pipeline by 4D Pharma Plc, H1 2020
  • Crohn's Disease (Regional Enteritis) - Pipeline by AbbVie Inc, H1 2020
  • Crohn's Disease (Regional Enteritis) - Pipeline by Abivax SA, H1 2020
  • Crohn's Disease (Regional Enteritis) - Pipeline by Aclaris Therapeutics Inc, H1 2020
  • Crohn's Disease (Regional Enteritis) - Pipeline by Active Biotech AB, H1 2020
  • Crohn's Disease (Regional Enteritis) - Dormant Projects, H1 2020
  • Crohn's Disease (Regional Enteritis) - Discontinued Products, H1 2020
  • Crohn's Disease (Regional Enteritis) - Discontinued Products, H1 2020 (Contd..1), H1 2020

List of Figures

  • Number of Products under Development for Crohn's Disease (Regional Enteritis), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Top 10 Routes of Administration, H1 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2020
  • Number of Products by Top 10 Molecule Types, H1 2020
  • Number of Products by Stage and Top 10 Molecule Types, H1 2020
目次
Product Code: GMDHC11988IDB

Summary

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Crohn's Disease - Pipeline Review, H1 2020, provides an overview of the Crohn's Disease (Gastrointestinal) pipeline landscape.

Crohn's disease is an inflammatory bowel disease (IBD). It causes inflammation of the lining of digestive tract, which can lead to abdominal pain, severe diarrhea and even malnutrition. Inflammation caused by Crohn's disease can involve different areas of the digestive tract in different people. Signs and symptoms may include diarrhea, abdominal pain and cramping, blood in stool, ulcers, reduced appetite and weight loss. Risk factor include age, family history, smoking and use of Non-steroidal anti-inflammatory medications.

Report Highlights

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Crohn's Disease - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Crohn's Disease (Gastrointestinal), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Crohn's Disease (Gastrointestinal) pipeline guide also reviews of key players involved in therapeutic development for Crohn's Disease (Regional Enteritis) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 4, 15, 36, 30, 1, 70, 19 and 1 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 1, 3 and 2 molecules, respectively.

Crohn's Disease (Gastrointestinal) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

  • The pipeline guide provides a snapshot of the global therapeutic landscape of Crohn's Disease (Gastrointestinal).
  • The pipeline guide reviews pipeline therapeutics for Crohn's Disease (Gastrointestinal) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Crohn's Disease (Gastrointestinal) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Crohn's Disease (Gastrointestinal) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Crohn's Disease (Gastrointestinal)

Reasons to buy

  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Crohn's Disease (Gastrointestinal).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Crohn's Disease (Gastrointestinal) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Table of Contents

Introduction

  • Crohn's Disease (Regional Enteritis) - Overview
  • Crohn's Disease (Regional Enteritis) - Therapeutics Development
  • Crohn's Disease (Regional Enteritis) - Therapeutics Assessment
  • Crohn's Disease (Regional Enteritis) - Companies Involved in Therapeutics Development
  • Crohn's Disease (Regional Enteritis) - Drug Profiles
  • Crohn's Disease (Regional Enteritis) - Dormant Projects
  • Crohn's Disease (Regional Enteritis) - Discontinued Products
  • Crohn's Disease (Regional Enteritis) - Product Development Milestones
  • Appendix